Objectives-Controversy exists over the effect of acute hyperglycemia on vascular function. In this systematic review, we compared the effect of acute hyperglycemia on endothelial and vascular smooth muscle functions across healthy and cardiometabolic diseased subjects. Approach and Results-A systematic search of MEDLINE, EMBASE, and Web of Science from inception until July 2014 identified articles evaluating endothelial or vascular smooth muscle function during acute hyperglycemia and normoglycemia. Meta-analyses compared the standardized mean difference (SMD) in endothelial and vascular smooth muscle functions between acute hyperglycemia and normoglycemia. Subgroup analyses and metaregression identified sources of heterogeneity. Thirty-nine articles (525 healthy and 540 cardiometabolic subjects) were analyzed. Endothelial function was decreased (39 studies; n=1065; SMD, −1.25; 95% confidence interval, −1.52 to −0.98; P<0.01), whereas vascular smooth muscle function was preserved (6 studies; n=144; SMD, −0.07; 95% confidence interval, −0.30 to 0.16; P=0.55) during acute hyperglycemia compared with normoglycemia. Significant heterogeneity was detected among endothelial function studies (P<0.01). A subgroup analysis revealed that endothelial function was decreased in the macrocirculation (30 studies; n=884; SMD, −1.40; 95% confidence interval, −1.68 to −1.12; P<0.01) but not in the microcirculation (9 studies; n=181; SMD, −0.63; 95% confidence interval, −1.36 to 0.11; P=0.09). Similar results were observed according to health status. Macrovascular endothelial function was inversely associated with age, blood pressure, and low-density lipoprotein cholesterol and was positively associated with the postocclusion interval of vascular assessment. Conclusions-To our knowledge, this is the first systematic review and meta-analysis of its kind. In healthy and diseased subjects, we found evidence for macrovascular but not microvascular endothelial dysfunction during acute hyperglycemia. (D.M.) . The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T he prevalence of type 2 diabetes mellitus represents a major public health issue, directly affecting an estimated 312 million people worldwide. 1 This burden is projected to worsen due, in part, to increasingly sedentary lifestyles and unhealthy dietary habits predominantly characterized by an excess consumption of added sugars. [2] [3] [4] Habitual consumption of added sugars, most commonly in the form of sugarsweetened beverages, is strongly associated with an increased risk in developing type 2 diabetes mellitus, as well as metabolic syndrome and obesity. [5] [6] [7] [8] In addition, consumption of added sugars has been linked to an increased risk of developing cardiovascular disease (CVD), which is the leading cause of mortality among those with cardiometabolic disease. 1, 9, 10 Consumption of excess added sugars leads to acute hyperglycemia, which is considered a better predictor of future CVD events than fasting glycemia in healthy and diabetic populations. 11, 12 Indeed, such acute hyperglycemic stress has also been proposed to contribute to vascular dysfunction, 13 which represents one of the main precursors to CVD. 14 In normal vascular function, the endothelium and vascular smooth muscle (VSM) cells continuously interact to regulate vasodilation and vasoconstriction, maintaining optimal organ perfusion and vascular tone. 15, 16 During acute hyperglycemia, increased oxidative stress has been proposed as a key trigger of vascular dysfunction by reducing nitric oxide (NO) production or NO bioavailability. 15, 17, 18 Furthermore, animal and in vitro studies suggest that acute hyperglycemia may also impair VSM function by disrupting VSM cell apoptosis, causing subsequent VSM cell proliferation and desensitization to NO. [19] [20] [21] However, whether endothelial and VSM functions are transiently impaired during acute hyperglycemia in humans is unclear because of discrepant results. Given this, we conducted a systematic review and meta-analysis of available studies comparing endothelial function alone or in combination with VSM function during acute hyperglycemia in healthy and cardiometabolic diseased individuals. To our knowledge, this represents the first systematic review and meta-analysis to assess the effect of acute hyperglycemia on vascular function.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Study Selection and Characteristics
A flowchart of study selection is shown in Figure 1 . The systematic search resulted in the inclusion of 39 from 394 potential articles. Fourteen of these articles reported vascular data for multiple subgroups of a given or diverse health status; thus, they were assessed as individual studies. 22, [25] [26] [27] [28] 31, 37, 38, 45, 52, [56] [57] [58] [59] The main characteristics and clinical data for these studies are shown in Tables 1 and 2, respectively. Three potentially relevant studies were not available for full text reading and thus could not be included. [61] [62] [63] All studies assessed endothelial or VSM function during acute hyperglycemia and normoglycemia in a total of 1065 individuals classified as healthy (n=525), obese (n=72), impaired glucose tolerance (n=104), type 2 diabetes mellitus (n=229), hypertensive (n=94), metabolic syndrome (n=30), or type 1 diabetic mellitus (n=11).
Quality Assessment and Potential Bias
The quality of the studies was moderate-to-high. The mean score was 9.4±1.5 of possible 12 points ( Table 1 ). The quality of evidence for outcomes demonstrating the effect of acute hyperglycemia on vascular function was low-to-moderate (Table 3) . As for the evaluation of potential bias, the funnel plot (Figure 2 ), Begg and Mazumdar rank correlation test, and the Egger regression test suggested the presence of publication bias or other biases for the standardized mean difference (SMD) in endothelial function in the studies included in the meta-analysis (P<0.01 and P<0.01, respectively). There was no evidence of publication or other biases when assessing the SMD in VSM function in the studies included in the meta-analysis.
Endothelial Function
After data pooling, endothelial function was significantly decreased during acute hyperglycemia compared with normoglycemia (39 studies; n=1065; SMD, −1.25; 95% confidence interval [CI], −1.52 to −0.98; P<0.01; Figure 3 ). There was no difference between health groups in the SMD in endothelial function (P=0.13), but significant heterogeneity was detected (I 2 =87%; P<0.01). Subgroup analysis of the SMD in endothelial function revealed that macrovascular function was significantly decreased during acute hyperglycemia compared with normoglycemia (30 studies; n=884; SMD, −1.40; 95% CI, −1.68 to −1.12; P<0.01), whereas no significant decrease was found in the studies that assessed microvascular endothelial function (9 studies; n=181; SMD, −0.63; 95% CI, −1.36 to 0.11; P=0.09). Heterogeneity was detected in the SMD in endothelial function for both macrovascular (I 2 =84%; P<0.01) and microvascular function studies (I 2 =90%; P<0.01). Of note, the heterogeneity about microvascular endothelial function was primarily explained (≈40%) by a single study, 30 and the exclusion of such study did not significantly alter the pooled effect size (8 studies; n=147; SMD, −0.18; 95% CI, −0.53 to 0.17; P=0.30).
VSM Function
After data pooling, VSM function was preserved during acute hyperglycemia versus normoglycemia (6 studies; n=144; SMD, −0.07; 95% CI, −0.30 to 0.16; P=0.55; Figure 4 ). There was no significant difference between health groups in the SMD in VSM function (P=0.49), and no heterogeneity was observed (I 2 =0%; P=0.85). Because of limited data availability, it was not possible to analyze macro-VSM and micro-VSM function separately. 
Nonstandard Abbreviations and Acronyms
Metaregression Analyses
The SMD in macrovascular endothelial function was inversely associated with age (β=−0.03; P<0.01), systolic blood pressure (β=−0.04; P<0.01), diastolic blood pressure (β=−0.05; P<0.01), mean arterial pressure (β=−0.05; P<0.01), and low-density lipoprotein cholesterol (β=−0.93; P<0.01; Figure 5 ). In turn, the SMD in macrovascular endothelial function was positively associated with the postocclusion interval of vascular assessment (β=0.36; P=0.01).
Ceriello et al B, 28 Some studies presented multiple health groups comparing normoglycemia and acute hyperglycemia vascular function and were therefore evaluated as individual studies (distinguished by A, B, C, or D). Authors who published multiple studies in a single year were distinguished by (1) or (2) . ↓ indicates significant decrease of vascular function during acute hyperglycemia compared with normoglycemia; ↔, no significant difference in vascular function between acute hyperglycemia and normoglycemia; ↑, significant increase of vascular function during acute hyperglycemia compared with normoglycemia; ACE, angiotensin-converting enzyme; ACh, acetylcholine; AH, acute hyperglycemia; EF, endothelial function; FMD, flow-mediated dilation; IGT, impaired glucose tolerance; IV, intravenous; MetS, metabolic syndrome; NA, vascular data not available; NMD, nitroglycerin-mediated dilation; OBS, observational study; OGTT, oral glucose tolerance test; PORH, postocclusive reactive hyperemia; RCT, randomized controlled trial; SNP, sodium nitroprusside; T1DM, type 1 diabetic mellitus; T2DM, type 2 diabetic mellitus; and VSMF, vascular smooth muscle function. Data are expressed as mean±SD or n. Some studies presented multiple health groups comparing normoglycemia and acute hyperglycemia vascular function and were therefore evaluated as individual studies (distinguished by A, B, C, or D). Authors who published multiple studies in a single year were distinguished by (1) or (2) . BMI indicates body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; MAP, mean arterial pressure; MetS, metabolic syndrome; NA, data not available; T1DM, type 1 diabetic mellitus; T2DM, type 2 diabetic mellitus; and SBP, systolic blood pressure. 
Discussion
To our knowledge, this is the first systematic review and meta-analysis to assess the effect of acute hyperglycemia on vascular function. Data from 39 studies assessing endothelial function alone or in combination with VSM function during acute hyperglycemia in healthy and cardiometabolic diseased individuals were pooled and analyzed. The meta-analysis provided evidence that the average effect of acute hyperglycemia on endothelial function is decreased function, whereas VSM function was preserved in healthy and diseased individuals. Because of evidence of heterogeneity, the interpretation of the pooled effects of hyperglycemia on endothelial function should be made cautiously. Considerable heterogeneity was identified for most subgroups suggesting that the variability across studies was because of not only sampling variability but also differences in treatment effect within each study. 64 Nevertheless, the large effect sizes and 95% CIs consistently favored normoglycemia, providing evidence of treatment effect. 64 Exploration of heterogeneity with metaregression indicated that the variability across studies could be explained by differences in age, blood pressure, and low-density lipoprotein cholesterol and the postocclusion interval of vascular assessment. Currently, there is no consensus on the effect of acute hyperglycemia on endothelial function and VSM function as studies assessing vascular function during acute hyperglycemia have presented confounding results. This meta-analysis demonstrated evidence of macrovascular endothelial dysfunction during acute hyperglycemia in healthy people, as well as cardiometabolic diseased subjects, suggesting that the pathogenesis of CVD may begin, among others, with acute hyperglycemia-mediated transient decreases in endothelial function long before the onset of morbidities, such as obesity, hypertension, or type 2 diabetes mellitus. Interestingly, the inverse ‡No control population included, failure to adequately control for confounding, and incomplete follow-up when assessing microvascular endothelial function. §Large I 2 and point estimates vary widely across studies assessing microvascular endothelial function suggesting benefit, harm, and no effect of acute hyperglycemia. ║The 95% confidence interval of the pooled risk ratio includes both positive and negative effects of acute hyperglycemia. ¶Publication bias is strongly suspected because of the presence of asymmetry in funnel plots for randomized control trials assessing endothelial, macrovascular endothelial, and microvascular endothelial function during hyperglycemia. relationship between macrovascular endothelial function and several traditional cardiovascular risk factors demonstrates the degree to which acute hyperglycemia mediates macrovascular endothelial dysfunction and correlates with increases in age, blood pressure, or low-density lipoprotein cholesterol levels. This is consistent with previous research revealing that elderly, hypertensive and subjects with dyslipidemia all exhibited significantly decreased endothelium-dependent vasodilation at rest compared with healthy populations, [65] [66] [67] indicating that any existing macrovascular endothelial dysfunction may therefore be compounded by an acute hyperglycemic stress. The fact that microvascular endothelial dysfunction during acute hyperglycemia was not detected contradicts previously published data that associates decreased microvascular function with incident type 2 diabetes mellitus and suggests a role for microvascular dysfunction in the pathogenesis of type 2 diabetes mellitus. 68 Although in this meta-analysis, macrovascular endothelial function was affected across healthy and cardiometabolic health groups, VSM function remained preserved during acute hyperglycemia when compared with normoglycemia. In contradiction to previous findings in animal and in vitro studies, which found VSM dysfunction mediated by VSM cell proliferation may occur in as little as 6 hours. 20, 52 Macrovascular endothelial dysfunction observed during acute hyperglycemia by methods assessing endothelium-dependent vasodilation primarily implicate decreased NO bioavailability as a central mechanism of endothelial dysfunction in healthy and cardiometabolic diseased populations. 69 This may be attributed to acute hyperglycemia increasing oxidative stress and its role in disrupting pathways of NO synthesis. 12 The fact that even healthy people exhibited decreased macrovascular endothelial function during acute hyperglycemia demonstrates how acutely NO bioavailability may be affected by excess sugar consumption. The magnitude of macrovascular endothelial dysfunction induced by acute hyperglycemia may be compounded when cardiovascular risk factors, such as increased age, blood pressure, or low-density lipoprotein cholesterol, are present. This may be partly due to the fact that health groups exhibiting these clinical markers demonstrate decreased NO bioavailability and therefore impaired endothelial function, even at rest. [65] [66] [67] Although NO is the predominant vasodilator in macrocirculation, it has been demonstrated to have significantly less influence in the microcirculatory system. 70 The increased influence of other chemical mediators of vasodilation, such as endothelial-derived hyperpolarizing factor and prostaglandin I 2 , 71 may, however, explain why microvascular endothelial function remained preserved during acute hyperglycemia. Consideration should also be given to the spatial variability associated with the techniques used in several of the studies using skin microcirculation as a model of assessing microvascular function. 72 The large spatial variability in single-point laser Doppler flowmetry, for example, may have limited findings. 73 Despite this, final conclusions on the effect of acute hyperglycemia on microvascular function should not be made because of the limited availability of microcirculation data. Furthermore, it must be acknowledged that shear stress was not considered when performing analyses of flow-mediated dilation data in many studies. Shear stress, which is responsible for inducing the NO release that causes flow-mediated dilation, is dependent on variability of the hyperemic blood flow response in the microcirculation. 74 Therefore, macrovascular endothelial dysfunction observed during acute hyperglycemia may partially be mediated by a decrease in shear stress stimulus reflecting microvascular dysfunction. 74 The fact that VSM function was preserved during acute hyperglycemia indicates that endothelial dysfunction precedes VSM dysfunction, further supporting its role as a primary mechanism of CVD pathogenesis. Although disruptions in NO bioavailability mediated by acute hyperglycemia and the resulting endothelial dysfunction may initially be transient, if repeated often enough, they may lead to cumulative adverse outcomes, including proinflammatory responses and VSM cell proliferation. 12, 75 It has been suggested that acute hyperglycemia may induce VSM cell proliferation by disrupting VSM cell apoptosis, which is a key mechanism to prevent increased neointimal formation and stenosis. 19 Moreover, decreased NO delivery by the endothelium to the VSM may contribute to VSM cell proliferation through increased periods of higher vasoconstrictive tone. 75 Ultimately, VSM cell proliferation may signal the beginning of a detectable and significant VSM dysfunction, representing a critical event in vascular remodeling and the development of CVD. 76 Given that CVD is the single leading cause of death, accounting for 30% of the annual global mortality rate, 77 and that even healthy populations are subject to vascular dysfunction during acute hyperglycemia, there is a clear need to further investigate the effects of acute hyperglycemia on the underlying mechanisms of vascular function in vivo. Because of a surge in added sugar consumption in recent decades, predominantly in the form of sugar-sweetened beverages, 2 humans are more often in a state of acute hyperglycemia and therefore are more frequently inducing endothelial dysfunction. Considering this, future research should quantify what frequency and dosage of sugar consumption mediate atherosclerotic vascular changes in healthy and cardiometabolic diseased populations. Previously, certain ethnicities have demonstrated decreased vascular function at rest compared with white subjects. 78 Whether this exacerbates any vascular dysfunction mediated by acute hyperglycemia is still unknown and requires further research. To provide more comprehensive conclusions on how macrovascular and microvascular functions are affected by acute hyperglycemia, future research should consider shear stress as a covariate of conduit artery flow-mediated dilation data during statistical analyses. 79, 80 Furthermore, noting that vascular function is not entirely mediated by NO, 12 future research may also investigate the effect of sugar-sweetened beverage consumption on numerous mechanisms of vasodilation (eg, NO, endothelium-derived hyperpolarizing factor, and prostaglandin I 2 ) and vasoconstriction (eg, endothelin-1), the influence of which varies from microcirculation to macrocirculation.
There are many inherent limitations to our analyses that require comment. As previously discussed, significant heterogeneity was observed among studies that assessed endothelial function. Studies published in languages other than English were not included, and the quality of evidence for outcomes assessed in this meta-analysis was low-to-moderate. Subanalyses of microcirculatory and VSM data were limited because of the low number of studies assessing microvascular and VSM function in normoglycemic and acute hyperglycemic states. Furthermore, some studies used methods of assessing microcirculation that can be easily influenced by spatial variability and thus may limit results when assessing microvascular function. The risk of publication or other biases was detected when assessing the SMD in endothelial function. However, the quality of studies was evaluated by specific tools for the quality assessment of observational research, 81, 82 revealing a predominantly low-bias risk. It must be acknowledged that the ethnicity of the populations was poorly reported by studies included in this meta-analysis, and thus, conclusions on the effect of ethnicity cannot be drawn from these data. Finally, many studies using flow-mediated dilation as a method of assessing macrovascular endothelial function did not report shear stress. Therefore, it was not possible to comprehensively conclude whether macrovascular endothelial dysfunction found during acute hyperglycemia is because of intrinsic abnormalities of macrovascular endothelial function or if it is partially attributable to microvascular dysfunction and decreased stimulus for conduit artery dilation. 79 In conclusion, based on studies included in this metaanalysis, current evidence suggests that acute hyperglycemia decreases macrovascular endothelial function with no changes in microvascular endothelial function and systemic VSM function across healthy and cardiometabolic populations. This further supports endothelial dysfunction mediated by decreased NO availability as a primary mechanism in the pathogenesis of CVD, which may begin long before vascular remodeling is detectable or the onset of cardiometabolic diseases. Noting that microvascular data were limited, the microcirculatory system should therefore not be dismissed as a possible site of vascular dysfunction. Considering this, future studies should investigate the effects of sugar-sweetened beverage consumption on the underlying mechanisms of human vascular function at microvascular and macrovascular levels. These studies will provide a better understanding of how acute hyperglycemia induces vascular dysfunction and how it contributes to the pathogenesis of CVD from healthy to cardiometabolic populations.
